Pharmaceutical Executive Daily: FDA's National Priority Voucher Program
Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.
The FDA has announced the launch of its National Priority Voucher Program, designed to accelerate the review of medicines that address critical public health challenges.
Modeled on existing priority review voucher frameworks, the initiative aims to incentivize development of therapies targeting urgent or underserved diseases.
Drugmakers whose products qualify will receive transferable vouchers that can shorten the review period for another drug or be sold to other companies.
Author's summary: FDA launches National Priority Voucher Program.